RNAs that function as negative gene regulators. miRNA deregulation is involved in the initiation and progression of human cancer; however, the underlying mechanism and its contributions to genome-wide transcriptional changes in cancer are still largely unknown. We studied miRNA deregulation in human epithelial ovarian cancer by integrative genomic approach, including miRNA microarray (n ‫؍‬ 106), array-based comparative genomic hybridization (n ‫؍‬ 109), cDNA microarray (n ‫؍‬ 76), and tissue array (n ‫؍‬ 504). miRNA expression is markedly down-regulated in malignant transformation and tumor progression. Genomic copy number loss and epigenetic silencing, respectively, may account for the downregulation of Ϸ15% and at least Ϸ36% of miRNAs in advanced ovarian tumors and miRNA down-regulation contributes to a genome-wide transcriptional deregulation. Last, eight miRNAs located in the chromosome 14 miRNA cluster (Dlk1-Gtl2 domain) were identified as potential tumor suppressor genes. Therefore, our results suggest that miRNAs may offer new biomarkers and therapeutic targets in epithelial ovarian cancer.
MicroRNAs (miRNAs) are an abundant class of small noncoding
RNAs that function as negative gene regulators. miRNA deregulation is involved in the initiation and progression of human cancer; however, the underlying mechanism and its contributions to genome-wide transcriptional changes in cancer are still largely unknown. We studied miRNA deregulation in human epithelial ovarian cancer by integrative genomic approach, including miRNA microarray (n ‫؍‬ 106), array-based comparative genomic hybridization (n ‫؍‬ 109), cDNA microarray (n ‫؍‬ 76), and tissue array (n ‫؍‬ 504). miRNA expression is markedly down-regulated in malignant transformation and tumor progression. Genomic copy number loss and epigenetic silencing, respectively, may account for the downregulation of Ϸ15% and at least Ϸ36% of miRNAs in advanced ovarian tumors and miRNA down-regulation contributes to a genome-wide transcriptional deregulation. Last, eight miRNAs located in the chromosome 14 miRNA cluster (Dlk1-Gtl2 domain) were identified as potential tumor suppressor genes. Therefore, our results suggest that miRNAs may offer new biomarkers and therapeutic targets in epithelial ovarian cancer.
Dlk1-Gtl2 domain ͉ noncoding RNA C ancer is a disease involving multistep changes in the genome. Studies on cancer genome have so far focused mainly on protein-coding genes, whereas little is presently known on alterations of functional noncoding sequences in cancer (1, 2) . MicroRNAs (miRNAs) are endogenous noncoding small RNAs, which negatively regulate gene expression (3) (4) (5) (6) . In human cancer, miRNAs might function as either oncogenes (7) (8) (9) (10) (11) or tumor suppressor genes (12) (13) (14) (15) . Increasing evidence shows that expression of miRNAs is deregulated in human cancer (1, 2) . High-throughput miRNA quantification technologies have provided powerful tools to study global miRNA profiles. It has become progressively obvious that, although the number of miRNAs (Ϸ600) is much smaller than that of the protein-coding genes (Ϸ22,000), miRNA expression signatures reflect more accurately the developmental lineage or tissue origin of human cancers (16) . Large-scale studies in human cancer further demonstrated that miRNA expression signatures are associated with specific tumor subtypes and clinical outcomes (16) (17) (18) (19) (20) (21) (22) . More than half of the miRNAs have been aligned to genomic fragile sites or regions associated with cancers (23) , and our group and others have provided evidence that miRNA genes are involved by copying abnormalities in cancer (7, 12, 24) . In addition, recent studies suggest that epigenetic alterations might play a critical role in regulating miRNA expression in human cancers (25) . Finally, several key proteins in the miRNA biogenesis pathway may be dysfunctional (26) or deregulated in cancer (27) (28) (29) (30) , which may enhance tumorigenesis (31) . Therefore, DNA copy number abnormalities, epigenetic alterations, and/or defects in the miRNA biogenetic machinery might each contribute to miRNA deregulation in human cancer.
Epithelial ovarian cancer (EOC), the most common ovarian malignancy, continues to be the leading cause of death among gynecological malignancies (24) . Here, we used integrative genomic approaches to perform a comprehensive analysis of miRNome alterations associated with malignant transformation of the ovarian surface epithelium and/or ovarian tumor stage progression. Our findings indicate that numerous miRNAs are down-regulated in EOC and that this down-regulation can be attributed to genomic copy number loss or more often to epigenetic silencing. Several important miRNA alterations with putative oncogenic or tumor suppressor function were found, including a miRNA cluster in Dlk1-Gtl2 domain that may represent an important therapeutic target in cancer.
Results

microRNA Expression Profiles Classify Malignant from Nonmalignant
Ovarian Surface Epithelium. Most EOC are believed to originate from the ovarian surface epithelium (OSE). Because the OSE represents only a minimal part of the whole normal ovary, whole ovary may not be a suitable normal tissue control for EOC (32) .
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To investigate miRNA alterations associated with OSE malignant transformation, we compared mature miRNA expression profiles in 18 EOC cell lines and four immortalized primary cultured human ovarian surface epithelium (IOSE), using TaqMan miRNA assay. Among 173 miRNAs examined, 160 miRNAs (92.5%) were detected in either IOSEs or EOC cell lines [supporting information (SI) Fig. S1 A] . Expression of select miRNAs (mir-15a, mir-30d, mir-182, mir-386, and let-7i) was further confirmed by Northern blot. Unsupervised hierarchical clustering or 3D scaling analysis clearly segregated the two groups of cells ( Fig. S1 A and B ). There were 35 miRNAs expressed differentially between the EOC and IOSE (P Ͻ 0.05). Only four (11.4%, 4/35) were up-regulated, whereas most (88.6%, 31/35) were down-regulated in EOC compared with IOSE lines (Fig. S1C and Dataset S1), including the tumor suppressor miRNAs let-7d (13, 14, 21) and mir-127 (25) . Thus, miRNAs are deregulated in EOC and can distinguish malignant from nonmalignant ovarian epithelium. Importantly, most miRNA alterations associated with ovarian epithelial transformation are consistent with down-regulation.
miRNA Down-Regulation in Late-Stage and High-Grade Ovarian Cancer. Next, we sought to identify miRNA alterations associated with ovarian cancer progression in vivo. We analyzed 106 primary human ovarian cancer specimens of various stages or grades, using miRNA microarrays. miRNA expression profiles of early-stage (I, n ϭ 25; II, n ϭ 8) and late-stage (III, n ϭ 62; IV, n ϭ 11) EOC were compared by significance analysis of microarrays. Expression of forty-four miRNAs were significantly different between early-and late-stage EOC. Interestingly, all miRNA alterations consisted in down-regulation in late-stage tumors. These alterations included three known tumor suppressors, miRNAs, mir-15a (12) , mir-34a, and mir-34b (15, (33) (34) (35) (36) (37) (Fig. 1A and Dataset S2). Ten miRNAs were found to be commonly down-regulated in both late-stage (relative to early tumors) and in EOC cells (relative to IOSE cells) ( Fig. 1D and Dataset S1 and Dataset S2). In addition, we analyzed miRNA expression differences between the low-grade (0, n ϭ 4; 1, n ϭ 18) and high-grade (2, n ϭ 17; 3, n ϭ 68) EOC. Thirteen miRNAs exhibited significant difference and all were down-regulated in high-grade compared with the low-grade EOC (Fig. 1B and Dataset S3). Ten of 13 miRNAs were commonly down-regulated with stage or grade advancement (Fig. 1D) . These results were further validated by stem-loop real-time RT-PCR. From 21 randomly selected miRNAs among the 44 that were downregulated in late stage, 17 were confirmed to be significantly down-regulated (P Ͻ 0.05, early stage n ϭ 30; late stage n ϭ 66) (Fig. S2 ). Four additional miRNAs were down-regulated in late stage but did not reach statistical significance (Fig. S2) . Because the prevalence of histotypes is different among EOC stages (nonserous histotypes prevail among early-stage tumors, whereas serous histotype prevails among late-stage tumors), we tested whether similar miRNA expression differences were detectable in a within-histotype analysis. We analyzed separately serous EOC samples, the most common EOC histotype. Again, we found that miRNA alterations consisted of down-regulation in late-stage or high-grade tumors ( Fig. 1C and Dataset S4 and Dataset S5). Taking the primary tumor microarray data and cell line TaqMan data together, we conclude that, during ovarian cancer tumorigenesis and progression, numerous miRNAs are down-regulated by as-yet-unknown mechanisms.
Drosha and Dicer Are Not Deregulated in Ovarian Cancer. The RNases Drosha and Dicer serve as key regulatory proteins in miRNA biogenesis pathway and their alterations may contribute to widespread miRNA deregulation in cancer (20, 31) . Thus, we examined the mRNA expression level of Drosha and Dicer in the same set of EOC samples used for miRNA microarray. There was no significant expression difference in Drosha or Dicer expression between early and late stage EOC (Fig. S3 A and B) . Similar levels of Drosha or Dicer were found also in EOC cell lines and IOSE ( Fig. S3 C and D) . Finally, similar levels of Drosha or Dicer were found in different stage EOC tumors in two independent public cDNA microarrays (Oncomine; Fig. S3  E and F) . Next, we analyzed the expression levels of Drosha and Dicer proteins in tissue arrays containing 504 EOC specimens. Immunostaining intensity of these proteins was scored as 1-4, and expression differences between early and late stages were examined by 2 test. Consistent with the mRNA expression levels, we did not find any significant difference in the expression of Drosha or Dicer between early-and late-stage tumors ( Fig. S3  G and H) . This result agrees with a recent report showing no substantial down-regulation of the miRNA processing machinery in human tumors (16) . To further assess the impact of Drosha or Dicer expression on EOC biology, we performed survival analysis using this tissue array. There was no correlation between the expression levels of either protein and the patient survival (Fig. S4) . These results indicate that the observed downregulation of numerous miRNAs in advanced EOC cannot be attributed to alterations in the key RNases of the miRNA biogenesis pathway. (23), and we have reported that genomic loci containing miRNA genes are frequently altered in human cancers (24) . Thus, we examined the chromosomal distribution of miRNAs that were found down-regulated in advanced EOC. Twenty-five of the miRNAs that were downregulated in late-stage EOC aggregate in Ͻ1-Mb clusters in three chromosomes (Fig. S5 ). These clustered miRNA loci were considered chromosome regions of interest in further aCGH analysis. We first analyzed miRNAs that are deregulated in EOC cell lines. We excluded mir-222, mir-224, and mir-424, which are located in chromosome X (not included in our aCGH platform), and mir-124, which exhibits multiple copies in different genomic loci. The remaining 31 miRNA are located in 17 euchromosomic loci. Two of four (50.0%) loci containing miRNA up-regulated in EOC lines relative to IOSE (mir-182 and mir-103) exhibited amplification ( Fig. 2A) . Two of 13 (15.3%) loci containing miRNA down-regulated in EOC lines relative to IOSE (mir-140 and mir-184) exhibited deletion ( Fig. 2 A) . Next, we analyzed miRNAs down-regulated in late-stage EOC, again excluding miRNAs located in chromosome X and miRNAs with multiple copies in different genomic loci. This analysis comprised 30 miRNAs located in 16 euchromosomic loci. Two of 16 loci (12.5%, mir-15a and mir-184) were significantly deleted. None of these loci exhibited amplification in late-stage EOC (Fig. 2B) .
To further confirm that DNA copy number alterations correlate with concordant miRNA deregulation in EOC, we analyzed two representative miRNAs with opposite alterations. We found that locus chr7129-130, containing mir-182, was amplified in 28.9% of EOC (Fig. S6A) . In both primary tumors and cell lines, DNA copy number amplification correlated with miRNA expression (Fig. S6 B and C) . Importantly, forced expression of mir-182 in EOC cell line significantly promoted tumor growth in vivo, confirming the role of mir-182 as a putative oncogene (unpublished data). We also analyzed mir-15a, a known tumor suppressor gene (12, 38, 39) . mir-15a was deleted in 23.9% of EOC (Fig. S6D) . A positive correlation between the deletion of locus chr1349-50 and reduced expression of mir-15a was found in both primary tumors and cell lines (Fig. S6 E-G) . Thus, DNA copy number alteration is one important mechanism of miRNA deregulation in EOC.
Epigenetic Alterations Silence miRNA Expression. Epigenetic mechanisms play an important role in chromatin remodeling and the regulation of protein-coding genes and miRNA in human cancer (25) . Importantly, three genomic loci at chromosomes 14, 19, and X harbor 25 miRNAs down-regulated in EOC (Fig. S5 ), and these loci may be regulated through imprinting or epigenetic mechanisms (40) . Therefore, we analyzed IOSE and EOC cell lines by real-time RT-PCR for expression of 18 from these 25 clustered miRNAs and 5 miRNAs not located in these clusters. mir-127 was chosen as experimental control, because it is epigenetically regulated in human cancer (25) . All eight miRNAs located in chromosome 14 cluster (mir-337, mir-432, mir-495, mir-368, mir-376a, mir-376b, mir-377, and mir-419) were expressed in all four IOSE, but in no EOC cell line. None of the six miRNAs located in chromosome 19 cluster (mir-520e, mir519e, mir-519d, mir-516, mir-518a, and mir-372) were detected in IOSE or EOC cell lines. Finally, three of four miRNAs located in chromosome X cluster (mir-448, mir-507, and mir-424) were expressed in both IOSE and EOC cell lines (Fig. 3A) .
To investigate whether epigenetic mechanisms are responsible for miRNA down-regulation in EOC, five EOC cell lines were treated with the DNA demethylating agent 5-aza-2Ј-deoxycytidine (5-Aza-CdR) and the histone deacetylase (HDAC) inhibitor 4-phenylbutyric acid (PBA) (25) . Seven of eight miRNAs at the chromosome 14 cluster, six of six miRNAs at the chromosome 19 cluster, two of four miRNAs at the chromosome X cluster, and one of five miRNAs located at other chromosomes were up-regulated by this treatment in at least two cell lines (Fig.  3B) . Interestingly, treatment restored the expression of miR-34b, a tumor suppressor miRNA regulated by p53, in all six cell lines. This result was also confirmed by Northern blot (Fig. S7 A and  B) . Taken together, expression of at least 16 of 44 (36.4%) miRNAs that are down-regulated in late-stage EOC was restored by DNA demethylation or histone deacetylase inhibiting drugs. These in vitro results suggest that epigenetic silencing is an important mechanism contributing to the widespread miRNA down-regulation in late-stage EOC.
MicroRNA Deregulation Affects mRNA Transcripts. miRNAs can down-regulate mRNA expression by controlling mRNA stability or cleaving target mRNAs. We then asked whether the marked down-regulation of miRNAs observed between early-and latestage EOC has implications on the transcriptome, i.e., whether it is associated with up-regulation of specific mRNAs. To address this question, we used Affymetrix cDNA microarrays to analyze the genome-wide transcriptional changes between early-and late-stage EOC in samples previously analyzed by miRNA microarray. In total, 76 EOC specimens (8 early-stage and 68 late-stage) were analyzed, and 2,279 transcripts were identified as significantly different between early-and late-stage EOC (P Ͻ 0.05). Of these, 1,266 were up-regulated in late-stage EOC. Thus, we collected 948 genes representing the 1,266 up-regulated Affymetrix transcripts and 15,212 annotated genes whose expression was unchanged between early-and late-EOC. Following the method described by Krutzfeld et al. (41) , we calculated the number of nonoverlapping occurrences of each possible hexamer in every 3Ј UTR sequence of those genes, divided it by the length of the UTR, and applied one-tailed Wilcoxon rank sum to each normalized hexamer count distribution in upregulated versus unchanged UTRs (Fig. 4 and Fig. S8 ). Several hexamers were significantly overrepresented in the up-regulated genes (P Ͻ 0.001) and in parallel corresponded to the first seed positions (miRNA nucleotides 1-6, 2-7, and 3-8) in miRNAs that were down-regulated in the late-stage EOC. Twelve miRNAs had seed region complementary to the top scoring hexamers (Fig. 4 and Fig. S8B ) and were considered significant candidates possibly contributing to the corresponding mRNA up-regulation in late-stage EOC. We also observed an enrichment in up-regulated genes for having at least two hexamers corresponding to the microRNA seed positions (Fig. S8C) . Of note, 5 of the top 12 miRNAs identified were located in the chromosome 14 cluster (Dlk1-Gtl2 domain) (42) (Fig. 4, Fig.  S5B, and Fig. S8B ). This finding indicates that miRNA alterations are not simply ''bystander events'' during EOC advancement but that they may serve as tumor suppressor genes whose loss mediates oncogenesis.
miRNA Cluster at Dlk1-Gtl2 Domain Is Commonly Altered in Epithelial
Cancers. Because mir-377, mir-368, and mir-495, three of the eight miRNAs located in the Dlk1-Gtl2 domain of chromosome 14, are also silenced by epigenetic mechanisms in bladder cancer (25) , we asked whether down-regulation of miRNAs in this cluster is a common molecular event in human epithelial malignancy. Four miRNAs in this cluster were randomly selected for the analysis in 23 benign breast lesions, 73 invasive ductal carcinomas (IDC), and paired colon cancer and normal colon tissue specimens from 18 patients. All miRNAs were down-regulated in tumors, with all but one (mir-376a) in breast cancer and one (mir-368) in colon cancer reaching statistical significance (Fig. S9) . Thus, down-regulation of chromosome 14 miRNA cluster is an event common to many human epithelial tumors. The above results collectively suggest that those eight miRNAs located in chromosome 14 cluster (Dlk1-Gtl2 domain) are commonly regulated and may play a role as tumor suppressor genes in solid tumors, because (i) they are downregulated in advanced relative to early-stage EOC and in invasive breast and colon cancer, (ii) they are silenced by epigenetic alterations in EOC and bladder cancer (25) , and (iii) their downregulation is associated with up-regulation of numerous potential mRNA targets in late-stage EOC. Importantly, this chromosome region has been identified as a cancer susceptibility locus in mouse (43) . Therefore, we further analyzed the putative mRNA targets of these eight miRNAs. mRNA targets identified with the above method for each of these miRNAs are listed in Dataset S6. Gene ontology (GO) analysis (18) revealed that these miRNAs are highly associated with two important biological processes implicated in human carcinogenesis, namely cell cycle regulation and immune response (Dataset S7).
Down-Regulation of miRNA Cluster at Dlk1-Gtl2 Domain Is Associated with Poor Survival. We asked whether deregulation of the miRNAs at the Dlk1-Gtl2 domain affects tumor behavior at an advanced stage. Nonsupervised clustering of eight Dlk1-Gtl2 domain miRNA expression signature classified 73 late-stage EOC in two distinct clusters, cluster 1, with global low expression of these miRNAs (n ϭ 38), and cluster 2, with relatively global high expression (n ϭ 35) (Fig. 5A) . Sixty-four tumors with histological sections and clinical follow-up were available for analysis. Patients in cluster 1 were at significantly greater risk with shorter 5-year survival than those in cluster 2 (P ϭ 0.024, log-rank test, Fig. 5B ). Because miRNAs located at Dlk1-Gtl2 domain appear to regulate mRNAs involved in the control of cell cycle, we examined the tumor proliferation index (percentage of Ki67-positive cells in tumor islets). Tumors in cluster 1 exhibited significantly higher proliferation index (49.0) than cluster 2 (32.7, P ϭ 0.017, Fig. 5 C-E) . Thus, down-regulation of miRNAs located at Dlk1-Gtl2 domain is associated with higher tumor proliferation and shorter patient survival.
Discussion
According to recent high-throughput studies, global expression of miRNAs is seemingly deregulated in most cancer types (1, (16) (17) (18) (19) (20) . Interestingly, miRNA expression may be widely downregulated in human tumors relative to normal tissues, as revealed by bead-based flow cytometry (16) or miRNA microarray (44). However, other microarray studies reported a tumor-specific mixed pattern of down-regulation and up-regulation of select miRNA genes (17) (18) (19) . The choice of control samples may therefore be critical in the interpretation of those results. For example, normal ovaries are mainly comprised of stroma and the surface epithelium represents only a minimal part; thus, the whole ovary may not serve as an optimal control for EOC studies. We accordingly compared EOC cell lines with ovarian surface epithelial cells to investigate the miRNA alterations associated with OSE malignant transformation. Our findings indicate that the miRNome is largely down-regulated in association with OSE malignant transformation and EOC progression, which is in agreement with recent reports (45, 46) . This result further suggests that certain miRNAs may function as tumor suppressor genes and justifies why abrogation of miRNAs at large may in fact be a hallmark of human cancers (16). DNA copy number abnormalities (23, 24) , epigenetic alterations (25), mutations (17) , transcriptional deregulation (15), and defective miRNA biogenesis pathway (31) may contribute to the miRNA deregulation in human cancer. In EOC, we showed that: (i) Drosha and Dicer, key proteins in miRNA biogenesis pathway, are not altered and, thus, are unlikely to contribute to the miRNA deregulation between early-and late-stage EOC; (ii) deletions occur in up to 15% of genomic loci harboring miRNAs that are downregulated, suggesting that genomic loss contributes to miRNA down-regulation in EOC; and (iii) at least one-third of downregulated miRNAs may be silenced by epigenetic alterations. For example, miR-15a was down-regulated and its DNA copy number was deleted in EOC. miR-34b, a tumor suppressor miRNA regulated by p53 (15, (33) (34) (35) (36) (37) , was also down-regulated in EOC but because of epigenetic silencing. Complementary mechanisms, including transcriptional regulation, may cooperate in miRNA deregulation. For example, mir-34b is regulated by p53, and p53 loss could cooperate with epigenetic mechanisms to down-regulate mir-34b. However, different mechanisms may regulate miRNA in opposite directions. For example, genomic gain may increase mir-182 expression in EOC, but mir-182 is silenced epigenetically in some EOC cell lines (Fig. 5B ) and bladder cancer (25) . Thus, final expression will depend on the net effect of these mechanisms. In addition, this study carried out the very first analysis to link miRNA microarray to cDNA microarray data to provide, through seed sequences, molecular evidence that miRNA down-regulation can indeed result in specific genome-wide transcriptional up-regulation.
Finally, a putative tumor suppressor miRNA cluster located at chromosome 14 (Dlk1-Gtl2 domain) was identified. This chromosome region is a cancer susceptibility locus in the mouse (43) and AAV integration in this location induced hepatocellular carcinoma (47) . Eight miRNAs located in this cluster are of particular interest, because they were suppressed in EOC cell lines in advanced EOC and invasive breast and colon cancer, they were silenced by epigenetic mechanisms, and they were predicted to up-regulate a large number of mRNA transcripts in late stage EOC that, by GO analysis, are implicated in cancer. Some of these miRNAs are also down-regulated in bladder cancer (25) . miRNAs in this chromosome region are only expressed from a maternally inherited chromosome and their imprinted expression is regulated by an intergenic germ line-derived differentially methylated region located Ϸ200 kb upstream of the miRNA cluster (42) . Importantly, tumors with lower expression of these eight miRNAs were associated with higher proliferation index and significantly shorter survival. At this point, the function of this miRNA cluster is largely unknown, but it may play a critical role in embryonic development (42, 48, 49) . Our data suggest that miRNAs in this cluster function as tumor suppressor genes. Further work is required to understand their function and potential for cancer therapy.
Materials and Methods
Patients and Specimens. The ovarian cancer (miRNA microarray, n ϭ 106; aCGH, n ϭ 109; Affymetrix cDNA microarray, n ϭ 76; tissue array, n ϭ 504; and qPCR validation, n ϭ 96) and breast cancer (n ϭ 96) specimens were collected at the University of Pennsylvania; the University of Turin, and the University of Helsinki. Detailed information is provided in SI Methods. The colon cancer and paired normal control specimens (n ϭ 18 pairs) were provided by the cooperative human tissue network (Cooperative Human Tissue Network) and the Department of Surgical Oncology, Okayama University.
TaqMan miRNA Assay. Expression of mature miRNAs was analyzed by TaqMan miRNA Assay (Applied Biosystems). Detailed information is provided in SI Methods.
miRNA Microarray. miRNA microarray was performed on the microarray chip (OSUCCC version 3.0; OSU). Detailed information is provided in SI Methods.
cDNA Microarray. cDNA microarray was performed on the human U133 ϩ 2.0 GeneChip (Affymetrix). Detailed information is provided in SI Methods.
Array-Based Comparative Genomic Hybridization (aCGH)
. BAC clones included in the 1-Mb array platform were described in ref. 24 . Detailed information is provided in SI Methods.
Tissue Microarray. The tissue microarray was constructed as described. A total of 504 specimens were printed in the array slides. Detailed information is provided in SI Methods. treatment with 5-Aza-CdR (3 M; Sigma-Aldrich) and/or PBA (3 mM; SigmaAldrich). 5-Aza-CdR was removed after 24 h, whereas PBA was continuously administered by replacing the medium containing PBA every 24 h for 6 days.
5-Aza
Bioinformatic Analysis. Detailed information for miRNA target prediction and gene ontology analysis is provided in SI Methods.
Statistics. Statistical analysis was performed by using the SPSS statistics software package (SPSS). All results were expressed as mean Ϯ SD, and P Ͻ 0.05 was used for significance. Kaplan-Meier curves were used to estimate 5-year rates and were compared with the use of log-rank statistics.
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SI Methods
Patients and Specimens. Clinical characteristics were as defined (1) . Optimal surgical debulking was Յ1 cm residual individual tumor nodules. Front-line chemotherapy comprised platinum, platinum-cyclophosphamide, or (after 1995) platinumpaclitaxel. Complete response to therapy was defined by normalization of physical examination, abdomino-pelvic CT scan and serum CA-125. Noncomplete response included partial response (Ն50% decrease in the sum of greater tumor dimensions by CT) and no response (Ͻ50% decrease or any increase in tumor). Progression-free survival was the time between completion of chemotherapy and first recurrence (if a complete response had been achieved) or progression, defined as Ն50% tumor increase by CT scan or two rising CA-125 values. Overall survival was the interval between diagnosis and death. Observation time was the interval between diagnosis and last contact (death or last follow-up). Time was censored at the last follow-up for patients without recurrence, progression or death. Nonserous tumors comprised serous, endometrioid, clear cell, and undifferentiated tumors. All tumors were from primary sites, and were immediately snap-frozen and stored at Ϫ80°C. Specimens were acquired and processed under procedures approved by the local IRBs and were compliant with the HIPAA act. RNA and DNA Isolation. Total RNA was isolated from 100-500 mg of frozen tissue or 1 ϫ 10 6 cultured cells with TRIzol reagent (Invitrogen). The quality and quantity of the isolated RNA was analyzed by using a Bioanalyzer 2100 system (Agilent). Genomic DNA was isolated from frozen tumors or cultured cells by overnight digestion, phenol-chloroform extraction, and ethanol precipitation.
TaqMan miRNA Assay. Expression of mature miRNAs were analyzed by TaqMan miRNA Assay (Applied Biosystems) under conditions defined by the supplier (3). Briefly, single-stranded cDNA was synthesized from 5.5 ng of total RNA in 15 l of reaction volume, using the TaqMan MicroRNA reverse transcription kit (Applied Biosystems). The reactions were incubated first at 16°C for 30 min, then at 42°C for 30 min. The reactions were inactivated by incubation at 85°C for 5 min. Each cDNA generated was amplified by quantitative PCR, using sequence specific primers from the TaqMan microRNA Assays Human Panel on an Applied Biosystems 7900HT Sequence Detection System (Applied Biosystems). The 20-l PCR included 10 l of 2ϫ Universal PCR Master Mix (No AmpErase UNG), 2 l of 10ϫ TaqMan MicroRNA assay mix, and 1.5 l of RT product. The reactions were incubated in a 384-well plate at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The threshold cycle (C T ) is defined as the fractional cycle number at which the fluorescence passes the fixed threshold (0.2). All signals with C T Ͻ 37.9 were set as undetermined.
miRNA Microarray. miRNA microarray was performed as described in ref. 4 . Briefly, 5 g of total RNA was reverse transcribed by using biotin end-labeled random-octamer oligonucleotide primer. Hybridization of biotin-labeled complementary DNA was performed on the Ohio State University miRNA microarray chip (OSUCCC version 3.0), which contains 1100 miRNA probes, including 326 human miRNA genes, spotted in duplicates. Often, more than one probe exists for a given mature miRNA. Additionally, there are quadruplicate probes corresponding to most premiRNAs. The hybridized chips were washed and processed to detect biotin-containing transcripts by streptavidin-Alexa647 conjugate and scanned on an Axon 4000B microarray scanner (Axon Instruments).
cDNA Microarray. A two-cycle amplification protocol (Affymetrix) was used to generate sufficient cRNA for microarray analysis according to the recommendations of the manufacturer. Briefly, 10 ng of total RNA was used in the first-round synthesis of double-stranded cDNA. The RNA was reverse transcribed by using a two-cycle cDNA synthesis kit (Affymetrix) followed by amplification, using a MEGAscript T7 kit (Ambion). The cRNA generated from the first-round synthesis was cleaned by using a GeneChip sample clean-up Module IVT column (Affymetrix). The second-round double-strand cDNA amplification was carried out by using an IVT labeling kit (Affymetrix). The resulting biotin-labeled cRNA was purified by using an IVT clean-up kit (Affymetrix) and quantified by using a UV spectrophotometer (A 260/280 ; Beckman). An aliquot (15 g) of cRNA was fragmented by heat and ion-mediated hydrolysis at 94°C for 35 min. Fragmented cRNA was hybridized in a hybridization oven (16 h at 45°C) to a human genome U133 Plus 2.0 GeneChip oligonucleotide array (Affymetrix) representing 47,000 transcripts and variants, including 38,500 well characterized human genes. The washing and staining of the arrays with phycoerythrinconjugated streptavidin (Molecular Probes) was completed in Fluidics Station 450 (Affymetrix). The arrays were subsequently scanned by using a confocal laser GeneChip Scanner 3000 and GeneChip operating software (Affymetrix).
Array-Based Comparative Genomic Hybridization (aCGH).
BAC clones included in the 1-Mb array platform were recently described in ref. 5 . Briefly, 4,134 clones from the CalTech A/B and RPCI-11 libraries were collected from both commercial and private sources and were mapped to build 34 of the human genome, using either an STS-marker (29%), end sequences (68%), or full sequences (3%). A minimum of two replicates per clone were printed on each slide. One g of tumor and reference DNA were labeled with Cy3 or Cy5, respectively (Amersham), using the BioPrime random-primed labeling kit (Invitrogen). In parallel experiments, tumor DNA and reference DNA were labeled with the opposite dye, to account for difference in dye incorporation and provide additional data for analysis. A systematic protocol was used to analyze aCGH data for copy number alterations. For quality control purposes, clones demonstrating an adjusted foreground to background intensity ratios of Ͻ0.8 in the reference channel were removed. With dye swap data merged as input, copy number breakpoints were estimated for each sample by the Circular Binary Segmentation (CBS) algorithm, using breakpoint significance based on 10,000 permutations (6) . Additional analyses and visualization of aCGH data were done by using the CGHAnalyzer software suite described in ref. 7 .
Tissue Microarray. The tissue microarray was constructed as described (8, 9) . Total 504 specimens were printed in the array slides. In brief, tumors were embedded in paraffin and 5-m sections were stained with hematoxylin-eosin to select representative regions for biopsies. Four core tissue biopsies were obtained from each specimen. The presence of tumor tissue on the arrayed samples was verified on hematoxylin-eosin stained section.
Microarray Analysis. The normalized microarray data were managed and analyzed by GeneSpring (Agilent), microarray software suite 4 (TM4; www.tm4.org) (10), BRB-ArrayTools version 3.6 (linus.nci.nih.gov/BRB-ArrayTools.html), and GenePattern (www.broad.mit.edu/cancer/software/genepattern) (11) . Cluster and TreeView (rana.lbl.gov/EisenSoftware.htm) was used for cluster analysis and tree visualization (12) .
Immunohistochemistry (IHC). IHC was performed by using the VECTASTAIN ABC Kit as described by the manufacturer (Vector). We used the following primary antibodies: mouse anti-human Dicer (13D6, 1:20; Abcam) and rabbit anti-human Drosha (1:200; Abcam), mouse-anti-human Ki67 (1:200; DAKO). Antibodies were incubated for 2 h at room temperature or overnight at 4°C. The immunoreaction was visualized with 3,3Ј-diaminobenzidine (Vector). Images were collected through Cool SNAP Pro color digital camera (Media Cybernetics) and staining index was analyzed by using Image-Pro Plus 4.1 software (Media Cybernetics).
Northern Blot Analysis. The 5Ј-digoxigenin labeled locked nuclear acid probes for miRNA detection were ordered from Exiqon. Five to 10 g of total RNA was loaded on a 15% TBE-Urea gel (Invitrogen) and electrophoresed at 180 V for 1.5 h. The gel was stained in 1x TBE plus 1 g/ml ethidium bromide for 40 min and photographed before electroblotting onto positively charged nylon membrane (Roche) in a TransBlot SD SemiDry electrophoretic transfer cell (Bio-Rad) at 20 V for 1.5 h. The membrane was hybridized with 100 ng/ml probe at 37°C overnight. On the following day, the membrane was washed twice in 2ϫ SSC at room temperature (21°C) for 5 min each and twice in 0.1ϫ SSC at 37°C for 15 min each. Digoxigenin signals were detected with DIG Northern Starter kit (Roche) following the manufacturer's instructions.
Microarray Data Retrieval. The public expression microarray data were retrieved from authors' web site and further analyzed by using the web-based microarray analysis software, ONCOMINE (www.oncomine.org) (13) .
Bioinformatic Analysis. 3ЈUTR sequences-The human 3ЈUTRs were extracted from Ensembl version 45 (dataset Homo sapiens genes National Center for Biotechnology Information 36). Affymetrix probe identifiers were mapped to Ensembl gene IDs, using BioMart (www.ensembl.org/biomart/martview). For each Ensembl gene, we used the longest 3ЈUTR transcript. 948 up-regulated and 15,212 unchanged 3ЈUTRs with the length of at least 30 and Ͻ10,000 nt were obtained. The one-tailed Wilcoxon rank sum test was performed by using R, for each hexamer occurrence distributions in up-regulated versus unchanged 3ЈUTRs.
Gene Ontology (GO) Analysis. FuncAssociate (with default settings) was used to search for GO attributes in which genes containing at least one of the hexamers corresponding to the miRNA were overrepresented (http://llama.med.har vard.edu/cgi/func/ funcassociate) (14) . For genes that are up-regulated in late EOC, we provide the number of hexamers that correspond to miRNAs from the Chr.14 cluster in Dataset S6, in which we also provide computational predicted nonconserved targets including 5Ј-dominant and 3Ј-compensatory target sites (15) and conserved targets as predicted from the programs TargetScan (16) and PicTar (17) , if available. 
Other Supporting Information Files
Dataset S1 Dataset S2 Dataset S3 Dataset S4 Dataset S5 Dataset S6 Dataset S7 Fig. S9 . miRNA cluster at the Dlk1-Gtl2 domain is altered in epithelial cancers. (A) miRNAs from the cluster located at the Dlk1-Gtl2 domain are down-regulated in invasive ductal carcinoma (IDC, n ϭ 73) compared with benign breast lesions (n ϭ 23). (B) miRNAs from this cluster are down-regulated in colon cancer compared with adjacent normal colon tissues (n ϭ 18).
